Treatment Strategy Helps People With Advanced Bladder Cancer Retain the Organ
TUESDAY, Oct. 10, 2023 (HealthDay News) — “Listen, I’m not a Pollyanna,” New Yorker David Cabelis makes clear. “I’m a cab driver.”“But I was diagnosed with this cancer,” the 72-year old said. “Bladder cancer, that’s what I had, and then I had this tr…
Learn MoreCombo Immunotherapy With Durvalumab Effective for NSCLC
MONDAY, Sept. 25, 2023 (HealthDay News) — For patients with resectable non-small cell lung cancer (NSCLC), combination immunotherapy with the anti-programmed death-ligand 1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab …
Learn MoreA Beginner’s Guide to Understanding Cancer Treatment Options
If you or a loved one has received a cancer diagnosis, you’re not alone. With approximately 1.9 million new cancer cases diagnosed annually, according to the American Cancer Society, that’s roughly 5,250 new cases every day in the United States.And af…
Learn MoreAtezolizumab Can Induce Response in Alveolar Soft Part Sarcoma
THURSDAY, Sept. 7, 2023 (HealthDay News) — The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS), according to a study published in the Sept. 7 issue of the New…
Learn MoreZolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma
FRIDAY, Sept. 1, 2023 (HealthDay News) — For patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma, zolbetuximab, a monoclonal …
Learn MoreSome Immunosuppressed Do Not Have Anti-Spike Antibodies After COVID-19 Vaccination
WEDNESDAY, Aug. 30, 2023 (HealthDay News) — About one in five immunosuppressed individuals have no detectable immunoglobulin (Ig)G anti-spike antibodies, even after three or more COVID-19 vaccines, according to a study published in the August issue o…
Learn MoreMost Immunosuppressive Drugs Not Linked to Risk for Cancer
MONDAY, Aug. 28, 2023 (HealthDay News) — For patients with ocular inflammatory disease (OID), short-term therapy with commonly used immunosuppressive drug classes and many drugs is not associated with an increased risk for cancer incidence, according…
Learn MoreNivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma
WEDNESDAY, Aug. 23, 2023 (HealthDay News) — For patients with metastatic melanoma who receive frontline anti-programmed death protein 1 (PD-1) or therapy against programmed cell death 1 ligand 1 and whose tumors progressed with cytotoxic T-lymphocyte…
Learn MoreImmune Checkpoint Inhibitors Can Be Active in Penile Cancer
WEDNESDAY, Aug. 23, 2023 (HealthDay News) — Immune checkpoint inhibitors (ICIs) are active in some patients with penile cancer (PeCa), according to a study published online Aug. 11 in the Journal of the National Cancer Institute.Talal El Zarif, M.D.,…
Learn MoreT-Cell Tolerant Fraction Can Predict Immunotherapy Toxicity
MONDAY, Aug. 21, 2023 (HealthDay News) — The T-cell tolerant fraction predicts clinically significant immune-related adverse events (irAEs) among patients with cancer treated with immune checkpoint inhibitors (ICIs), according to a study published in…
Learn More